J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH SIGNED A STRATEGIC COLLABORATION AGREEMENT WITH CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE ON OCTOBER 9, 2018

J. Michael Bishop Institute of Cancer Research (MBICR) Signed a Strategic Collaboration Agreement with Chengdu University of Traditional Chinese Medicine (CUTCM) on October 9, 2018. Therefore, the day marked a special day in the history of MBICR. The signing ceremony of the strategic cooperation agreement between CUTCM and MBICR was held at the Wenjiang campus of the CUTCM. This latest agreement, which was signed to advance cancer research, is the fourth collaboration agreement that MBICR has signed with a local research institution since its inauguration on December 30, 2016.

The Nobel Laureate Dr. J. Michael Bishop, chairman of the Scientific Advisory Board (SAB) of MBICR, led the members of the institute advisors that came in droves from the UK and the US to witness the glorious moment. The MBICR advisors who attended the event include professor Robert Lloyd FRS from the University of Nottingham, professor James Naismith FRS from the University of Oxford, professor Scott Kogan from the University of California, San Francisco, professor Dean Felsher from Stanford University, Dr. Dana Aftab from Exelixis, and the renowned Apple logo designer Rob Janoff and his colleagues.

Professor Shuguang Yu, the president of CUTCM, expressed his warm welcome to the arrival of MBICR employees and then delivered a keynote speech about the role of traditional Chinese medicines in the treatment of cancer. He said, “Cancer is becoming the primary cause of death in the 21st century and is one of the greatest health challenges for humanity today. Traditional Chinese medicine occupies a special position in the treatment of cancer. It has been successfully combined with radiotherapy and chemotherapy to reduce their toxicity and enhance treatment efficacy. It can effectively improve the immune status, stabilize the disease and prolong the survival of cancer patients.? MBICR is conducting translational research in the field of cancer cell biology, small RNA biology, cancer gene biology, cancer stem cells, and the CRISPR-Cas cellular immune system. The institute is striving to develop herbal therapeutics for the precision treatment of cancer. Our cooperation with MBICR will integrate the rich medicinal plant resources in the southwest region of China, excellent traditional Chinese medicine with the cutting-edge cancer research at MBICR to cope with the challenges from cancer.

Under the witness of MBICR employees and more than 300 faculty members and students of CUTCM, Dr. Dun Yang, Director of MBICR and Professor Tian Li, Vice-president of Clinical Medical College/Affiliated Hospitals of CUTCM signed a strategic cooperation agreement on behalf of both parties. The agreement involves extensive collaboration in graduate education, hiring principal investigators jointly, basic cancer research, and anticancer drug development.

After the ceremony, Dr. Dun Yang delivered a presentation on behalf of MBICR. His presentation intimated the members of the audience with the history, current status and future development plans of the MBICR, as well as the direction of its research and development of new anti-cancer drugs. In particular, he elaborated on the breakthrough made by MBICR in the screening synthetic lethal anticancer drugs from medicinal plants over the past two years. The approach may lead to the discovery of herbal therapeutics that treat cancer by using its oncogenic alterations without inhibiting them directly, having the potential to greatly broaden the repertoire of targeted therapies. It may also provide a scientific rationale to explain the variable therapeutic efficacy of some herbal formulas in the treatment of cancer.

?

Media Coverage

?

The signing ceremony has been heavy-covered by the following main media in China.

Sohu.com

ThePaper.cn

China News

Sichuan Daily

?

Intro to the Chengdu University of Traditional Chinese Medicine

万博体育 九州 365Chengdu University of Traditional Chinese Medicine (CUTCM) is located in the Chengdu, the capital city of Sichuan province, a place generally credited as the hometown of Traditional Chinese Medicine (TCM) and a treasure house of medicinal herbs.? Founded in 1956, CUTCM is one of the four earliest universities in China that were established especially to train specialists who research and practice TCM. A key university in Sichuan province and under co-administration by the provincial government and the State Administration of TCM, CUTCM has been recognized as Teaching Excellence by the National Evaluation of Undergraduate Education. The university provides 29, 49 and 16 programs for undergraduate, master and Ph.D. studies, respectively. Since early 1980, CUTCM has accepted foreign students from all over the world, having trained many international students in a large variety of programs, such as Chinese Medicine, Chinese Pharmacy, and Acupuncture.

The affiliated hospital of CUTCM is the most comprehensive and largest medical center that practices Chinese medicine in Southwest China. The hospital has established a Cancer Research Institute that routinely serves 4,000 inpatients and nearly 100,000 outpatients per year. The cancer institute puts its patients’ priorities at the center of its care and strives for breakthrough discoveries that improve people’s lives.? The institute is recognized nationally for clinical excellence in the treatment of tumors with traditional herbal medicine, research excellence in illustrating the mechanisms underlying tumorigenesis from the Chinese medicine perspective, and the demonstrated strength in the discovery and development of anticancer drugs from natural products.